Thyroid Clinical Trials
Here are the 6 most popular medical studies for thyroid
Cancer Vaccine
GI-6207 for Medullary Thyroid Cancer
Background: - GI-6207 is an experimental cancer vaccine made with baker's yeast. The yeast has been modified to help the immune system target a protein called CEA. CEA is found on the surface of some kinds of tumor cells, including thyroid cancer cells. Researchers want to see if GI-6207 can encourage the body's immune system to attack and kill tumor cells that contain the CEA protein. They will test to see whether this vaccine is a safe and effective treatment for medullary thyroid cancer that has not responded to earlier treatments. Objectives: - To test the safety and effectiveness of the GI-6207 vaccine for advanced medullary thyroid cancer. Eligibility: - Individuals at least 18 years of age who have medullary thyroid cancer that has not responded to earlier treatments. Design: Participants will be screened with a physical exam and medical history. They will provide blood and tumor samples and have an imaging study of the neck and chest. They will also have a skin test to make sure that they are not allergic to the yeast in the vaccine. Participants will be divided into two groups. One group will start to take GI-6207 immediately for 1 year. The second group will have 6 months of monitoring and tests with no vaccine, and then will take GI-6207 for 1 year. GI-6207 will be given every other week for the first seven visits (about 3 months), and then monthly for the remaining year of treatment. It will be given as injections beneath the arm and in the upper thigh. These locations will help the vaccine enter the lymph nodes and reach the immune system more quickly. Participants will be monitored with frequent blood and urine tests and imaging studies. Participants will have regular follow-up visits after their year of study vaccines.
SWUS Elastography for Thyroid Nodule
Shear wave ultrasound elastography is a new technique of finding the softness or hardness in tissue by applying a "push" generated by the machine. This technique will help in diagnosing malignancy in the thyroid gland without biopsy and avoiding biopsy in noncancerous nodules.
Thyroid Hormone Replacement
Levothyroxine +1 More for Hypothyroidism
Our hypothesis is that hypothyroid patients on DTE may have a decrease in symptoms, an improvement of cognitive function, and an increase in sense of well-being/ quality of life equivalently compared with L-T4.
Behavioural Intervention
CASAD for Diarrhea
Diarrhea in patients with MTC (Medullary Thyroid Cancer) can be debilitating and, in some cases life threatening. Findings in such patients include volume depletion, renal insufficiency, and electrolyte disorders. Diarrhea can also lead to increased cost of care, reduced quality of life, and treatment delays. Not all patients benefit from conventional anti-diarrheal therapy. CASAD is proven to reduce diarrhea in humans and animals. Clays have water-binding effects, increase the absorptive capacity of the intestinal mucosa, and absorb the excess cytokines which are possible mechanisms of diarrhea in MTC. In this study, we will investigate if starting 1 g CASAD three times a day will ameliorate the severity of diarrhea in patients with MTC. Diarrhea in patients with MTC can be debilitating and, in some cases life threatening. Findings in such patients include volume depletion, renal insufficiency, and electrolyte disorders. We hypothesize that adding CASAD 3 grams/day will reduce the incidence and ameliorate the severity of diarrhea in patients with MTC.
Popular filter options for thyroid trials
Thyroid Cancer Clinical Trials
View 50 Thyroid Cancer medical studies.
Tyrosine Kinase Inhibitor
Vandetanib for Thyroid Cancer
This trial is investigating the effects of the drug ZD6474 on patients with medullary thyroid cancer, in order to learn more about the drug's efficacy, side effects, and how it works in the human body.
Thyroid Carcinoma Clinical Trials
View 49 Thyroid Carcinoma medical studies.
Tyrosine Kinase Inhibitor
Vandetanib for Thyroid Cancer
This trial is investigating the effects of the drug ZD6474 on patients with medullary thyroid cancer, in order to learn more about the drug's efficacy, side effects, and how it works in the human body.
BRAF Positive Clinical Trials
View 15 BRAF positive medical studies.
MEK Inhibitor
Trametinib for Thyroid Cancer
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Phase 3 Thyroid Clinical Trials
View 97 phase 3 thyroid medical studies.
Parathyroid Hormone Analog
PTH(1-84) for Hypoparathyroidism
This is an open-label study of PTH(1-84) treatment that seeks: To determine the actions of PTH(1-84) to provide long term control of serum calcium and urinary calcium excretion with use of standard amounts of calcium and vitamin D supplementation. To determine the extent to which PTH(1-84) improves quality-of-life on long-term basis. To establish the safety of PTH(1-84) when administered for up to 12 years. To attempt to quantify improvements in the typical signs/symptoms of hypoparathyroidism post PTH administration. There will be one visit conducted every six months in the study offices of the principal investigator, Dr. John Bilezikian. In addition to these visits, there will be, for new patients who have not used PTH (1-84) before, a Screening Visit four weeks prior to the baseline visit for the purpose of performing screening labs as well as a Pre-Baseline Local Quest Lab performed to ensure stability prior to Baseline.
Parathyroid Hormone Analog
PTH1-84 for Hypoparathyroidism
The purpose of this protocol is to add on additional exploratory studies to investigate changes in bone quality parameters with PTH(1-84) treatment of hypoparathyroidism. In addition to the biochemical hallmarks of hypoPT, it has been found that the microscopic structure of the bone, as well as the bone remodeling system, are markedly abnormal in this disease. How these abnormalities may be corrected with PTH(1-84) administration are not fully understood. The studies outlined in this add-on protocol are designed to shed light on the mechanistic ways that PTH(1-84) replacement may restore normal bone metabolism. These mechanistic studies are beyond the scope of the parent NPS study, which was designed to assess the safety and efficacy of PTH(1-84) in hypoPT treatment. Subjects who are participating in the NPS' REPLACE, RELAY, and RACE Studies and the HEXT Study at Columbia University will be invited to participate in this add-on protocol, which will involve a separate IRB-approved informed consent. Study procedures: High Resolution Peripheral Quantitative Computed Tomography (HRpQCT; XtremeCT, Scanco): Done at the same visit as DXA. In the REPLACE study twice, in RELAY once (or not at all if done within the last 6 months), in RACE twice, and in HEXT three times. Osteolineage: At Baseline/Randomization/Visit One and at 4, 8, 12, 24, and 52 weeks of treatment in the REPLACE, RELAY, or RACE Study, if applicable, or at baseline and each 6-months visit in the HEXT Study, blood test for circulating osteogenic cells (10 cc) will be performed Sclerostin: At Baseline/Randomization/Visit One and at 4, 8, 12, 24, and 52 weeks of treatment in the REPLACE, RELAY, or RACE Study, if applicable, or at baseline and each 6-months visit in the HEXT Study, blood test for sclerostin (5cc) will be performed Funding Source - FDA OOPD
Tyrosine Kinase Inhibitor
Vandetanib for Thyroid Cancer
This trial is investigating the effects of the drug ZD6474 on patients with medullary thyroid cancer, in order to learn more about the drug's efficacy, side effects, and how it works in the human body.
Thyroid Clinical Trials With No Placebo
View 97 thyroid medical studies that do not have a placebo group.
Parathyroid Hormone Analog
PTH(1-84) for Hypoparathyroidism
This is an open-label study of PTH(1-84) treatment that seeks: To determine the actions of PTH(1-84) to provide long term control of serum calcium and urinary calcium excretion with use of standard amounts of calcium and vitamin D supplementation. To determine the extent to which PTH(1-84) improves quality-of-life on long-term basis. To establish the safety of PTH(1-84) when administered for up to 12 years. To attempt to quantify improvements in the typical signs/symptoms of hypoparathyroidism post PTH administration. There will be one visit conducted every six months in the study offices of the principal investigator, Dr. John Bilezikian. In addition to these visits, there will be, for new patients who have not used PTH (1-84) before, a Screening Visit four weeks prior to the baseline visit for the purpose of performing screening labs as well as a Pre-Baseline Local Quest Lab performed to ensure stability prior to Baseline.
Parathyroid Hormone Analog
PTH1-84 for Hypoparathyroidism
The purpose of this protocol is to add on additional exploratory studies to investigate changes in bone quality parameters with PTH(1-84) treatment of hypoparathyroidism. In addition to the biochemical hallmarks of hypoPT, it has been found that the microscopic structure of the bone, as well as the bone remodeling system, are markedly abnormal in this disease. How these abnormalities may be corrected with PTH(1-84) administration are not fully understood. The studies outlined in this add-on protocol are designed to shed light on the mechanistic ways that PTH(1-84) replacement may restore normal bone metabolism. These mechanistic studies are beyond the scope of the parent NPS study, which was designed to assess the safety and efficacy of PTH(1-84) in hypoPT treatment. Subjects who are participating in the NPS' REPLACE, RELAY, and RACE Studies and the HEXT Study at Columbia University will be invited to participate in this add-on protocol, which will involve a separate IRB-approved informed consent. Study procedures: High Resolution Peripheral Quantitative Computed Tomography (HRpQCT; XtremeCT, Scanco): Done at the same visit as DXA. In the REPLACE study twice, in RELAY once (or not at all if done within the last 6 months), in RACE twice, and in HEXT three times. Osteolineage: At Baseline/Randomization/Visit One and at 4, 8, 12, 24, and 52 weeks of treatment in the REPLACE, RELAY, or RACE Study, if applicable, or at baseline and each 6-months visit in the HEXT Study, blood test for circulating osteogenic cells (10 cc) will be performed Sclerostin: At Baseline/Randomization/Visit One and at 4, 8, 12, 24, and 52 weeks of treatment in the REPLACE, RELAY, or RACE Study, if applicable, or at baseline and each 6-months visit in the HEXT Study, blood test for sclerostin (5cc) will be performed Funding Source - FDA OOPD
View More Thyroid Trials
See another 70 medical studies focused on thyroid.
Frequently Asked Questions
Introduction to thyroid
What are the top hospitals conducting thyroid research?
When it comes to cutting-edge clinical trials focused on thyroid conditions, several top hospitals are making significant strides. One of these institutions is the Memorial Sloan Kettering Cancer Center located in New york City. With an impressive 14 active trials currently underway, this center is dedicated to advancing research and treatment options for patients with thyroid-related issues. Similarly, the M D Anderson Cancer Center in Houston stands out with 11 ongoing clinical trials specifically targeting thyroid disorders. Their commitment to exploring innovative approaches brings hope to those affected by thyroid conditions. Another prominent hospital contributing valuable insights is the Mayo Clinic in Rochester, which has a commendable eight active thyroid trials happening at present. This institution's dedication to improving patient care through scientific investigation makes them a leader in the field of thyrology.
The Ohio State University Comprehensive Cancer Center based in Columbus also plays a critical role in advancing our understanding of thyroid diseases through their five current clinical trials focusing on this area. By actively engaging in research and seeking breakthroughs, they aim to enhance treatment outcomes for individuals diagnosed with such conditions.
Even smaller-scale facilities like Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) located in Basking Ridge participate actively as well; despite having only four ongoing thyroid trials presently being conducted there, their contribution remains invaluable.
These esteemed hospitals collectively exemplify a commitment towards unravelling mysteries surrounding various aspects of thyrological complications that millions worldwide face every day.. Through collaborative efforts and unwavering determination, they strive toward discovering effective therapies that will ultimately improve lives and offer brighter futures for those impacted by these conditions
Which are the best cities for thyroid clinical trials?
When it comes to thyroid clinical trials, several cities in the United States lead the way in research and development. New york City boasts 27 active trials, exploring treatments like TransCon PTH, PET/CT Scan, and Vemurafenib. Houston, Texas follows closely behind with 22 ongoing studies focused on Pembrolizumab, pralsetinib (BLU-667), and Double-Blind Phase PLS240 among others. Boston, Massachusetts is also a hub for thyroid clinical trials with 19 active studies examining pralsetinib (BLU-667), Paricalcitol, Tirosint®-SOL, and more. Philadelphia and Rochester are additional key locations with significant ongoing research initiatives. These cities offer individuals dealing with thyroid conditions access to cutting-edge clinical trials that pave the way for advancements in treatment options and improve patient outcomes.
Which are the top treatments for thyroid being explored in clinical trials?
Clinical trials for thyroid treatments are underway, with several promising options currently being explored. Among the top contenders are:
- Lenvatinib: An active participant in multiple clinical trials, lenvatinib has shown potential as an effective treatment for thyroid conditions.
- Sorafenib: Another notable candidate, sorafenib is currently being investigated in various clinical studies focused on identifying its efficacy in treating thyroid-related ailments.
As researchers delve deeper into these clinical trials, they aim to uncover new and improved treatment options that can bring hope to individuals battling thyroid issues.
What are the most recent clinical trials for thyroid?
Recent clinical trials have explored new possibilities for the treatment of thyroid conditions. Among these studies is a Phase 2 trial investigating radioiodine-refractory, recurrent and/or metastatic differentiated thyroid cancer (DTC). Additionally, a Phase 3 trial is examining the efficacy of eneboparatide in patients with thyroid disorders. Another Phase 3 trial, known as Double-Blind Phase PLS240, focuses on evaluating a potential therapeutic option for individuals affected by thyroid-related issues. These ongoing trials offer hope for improved management and outcomes in patients with thyroid conditions.
What thyroid clinical trials were recently completed?
Recently, there have been several notable clinical trials focused on thyroid conditions that have reached completion. These trials aim to enhance our understanding and treatment options for thyroid-related disorders. One recent trial in particular investigated the potential benefits of a novel medication for treating hyperthyroidism. Another study examined the effectiveness of a targeted therapy for advanced thyroid cancer patients who had not responded well to standard treatments. These advancements signify important progress in the field and offer hope for individuals affected by thyroid disorders.